Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Фолликулярная лимфома
Фолликулярная лимфома
Бабичева Л.Г., Тумян Г.С., Османов Е.А. и др. Фолликулярная лимфома. Клинические рекомендации. Современная Онкология. 2020; 22 (2): 34–51. DOI:10.26442/18151434.2020.2.200131
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC). Ed. S.H.Swerdlow, E.Campo, N.L.Harris et al. 2017.
2. Armitage JO. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997; 89 (11): 3909–18.
3. Бабичева Л.Г., Тумян Г.С., Кравченко С.К. Фолликулярная лимфома. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 43–52.
[Babicheva L.G., Tumian G.S., Kravchenko S.K. Follikuliarnaia limfoma. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 43–52 (in Russian).]
4. Демина Е.А. и др. Общие принципы диагностики лимфом. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 9–27.
[Demina E.A. et al. Obshchie printsipy diagnostiki limfom. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 9–27 (in Russian).]
5. Мухортова О.В. Использование ПЭТ/КТ при лимфопролиферативных заболеваниях. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 168–79.
[Mukhortova O.V. Ispol'zovanie PET/KT pri limfoproliferativnykh zabolevaniiakh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 168–79 (in Russian).]
6. Криволапов Ю.А., Леенман Е.Е. Морфологическая диагностика лимфом. СПб.: Коста, 2006.
[Krivolapov Iu.A., Leenman E.E. Morfologicheskaia diagnostika limfom. Saint Petersburg: Kosta, 2006 (in Russian).]
7. Бокерия Л.А., Затевахин И.И., Кириенко А.И. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015; 4 (2): 3–52.
[Bokeriia L.A., Zatevakhin I.I., Kirienko A.I. Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniiu i profilaktike venoznykh tromboembolicheskikh oslozhnenii (VTEO). Flebologiia. 2015; 4 (2): 3–52 (in Russian).]
8. Кириенко А.И., Галстян Г.М., Савченко В.Г. Профилактика венозных тромбоэмболических осложнений при лимфопролиферативных заболеваниях. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 268–78.
[Kirienko A.I., Galstian G.M., Savchenko V.G. Profilaktika venoznykh tromboembolicheskikh oslozhnenii pri limfoproliferativnykh zabolevaniiakh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 268–78 (in Russian).]
9. Шмаков Р.Г., Демина Е.А. Лимфомы и беременность. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 143–50.
[Shmakov R.G., Demina E.A. Limfomy i beremennost'. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 143–50 (in Russian).]
10. Zelenetz AD et al. B-cell lymphomas. NCCN Clinical Practice Guidelines in Oncology. Version 5. 2019.
11. Dreyling M et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl. 5): v83–v90.
12. Campbell BA et al. Long-term outcomes for patients with limited stage follicular lymphoma involved regional radiotherapy versus involved node radiotherapy. Cancer 2010; 116 (16): 3797–806.
13. Wilder RB et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001; 51 (5) 1219–27.
14. Brady JL et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: A collaborative study by ILROG. Blood 2019; 133 (3): 237–45.
15. Ardeshna KM et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial. Lancet Oncol 2014; 15 (4): 424–35.
16. Hiddemann W et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol 2018; 36 (23): 2395–404.
17. Cheson BD et al. Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol 2018; 36 (22): 2259–66.
18. Flinn IW et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123 (19): 2944–52.
19. Dührsen U et al. Rituximab maintenance therapy of follicular lymphoma in clinical practice. Cancer Med 2018; 7 (7): 2903–12.
20. Поддубная И.В. Рецидивы фолликулярной лимфомы: проблемы и пути решения. Современная онкология. 2011; 1: 10–5.
[Poddubnaia I.V. Retsidivy follikuliarnoi limfomy: problemy i puti resheniia. Journal of Modern Oncology. 2011; 1: 10–5 (in Russian).]
21. Leonard JP et al. AUGMENT: A Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019; 37 (14): 1188–99.
22. Sehn LH et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 2016; 17 (8): 1081–93.
23. Godfrey J, Leukam MJ, Smith SM. An update in treating transformed lymphoma. Best Pract Res Clin Haematol 2018; 31 (3): 251–61.
24. Grignano et al. Radiotherapy of relapse-refractory follicular lymphoma. Cancer Radiother 2018; 22 (2): 126–30.
25. Attarbaschi A et al. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a "watch and wait" strategy after complete resection. Ann Hematol 2013; 92 (11): 1537–41.
26. Liu Q et al. Follicular lymphomas in children and young adults: A comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol 2013; 37 (3): 333–43.
27. Kumar R et al. Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma. Pediatr. Blood Cancer 2011; 57 (2): 317–20.
28. Cheson BD et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25 (5): 579–86.
29. Барях Е.А., Мякова Н.В., Поддубная И.В. Профилактика и лечение синдрома лизиса опухоли. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 251–3.
[Bariakh E.A., Miakova N.V., Poddubnaia I.V. Profilaktika i lechenie sindroma lizisa opukholi. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 251–3 (in Russian).]
30. Aapro M и др. Клинические рекомендации по лечению анемии у больных злокачественными новообразованиями. М.: Ассоциация онкологов России, 2014.
[Aapro M et al. Clinical recommendations for the treatment of anemia in patients with malignant neoplasms. Moscow: Association of Oncologists of Russia, 2014 (in Russian).]
31. Орлова Р.В. и др. Практические рекомендации по лечению анемии при злокачественных новообразованиях. Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018; с. 494–501.
[Orlova R.V. et al. Prakticheskie rekomendatsii po lecheniiu anemii pri zlokachestvennykh novoobrazovaniiakh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; p. 494–501 (in Russian).]
32. Владимирова Л.Ю. и др. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных. Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018; с. 502–11.
[Vladimirova L.Iu. et al. Prakticheskie rekomendatsii po profilaktike i lecheniiu toshnoty i rvoty u onkologicheskikh bol'nykh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; p. 502–11 (in Russian).]
33. Константинова Т.С., Клясова Г.А., Капланов К.Д. Лечение и профилактика инфекционных осложнений у пациентов с лимфопролиферативными заболеваниями. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 289–311.
[Konstantinova T.S., Kliasova G.A., Kaplanov K.D. Lechenie i profilaktika infektsionnykh oslozhnenii u patsientov s limfoproliferativnymi zabolevaniiami. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 289–311 (in Russian).]
34. Srivastava S, Wood P. Secondary antibody deficiency-causes and approach to diagnosis. Clin Med 2016.
35. Абузарова Г.Р. и др. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И.Пирогова Минздрава России, 2016.
[Abuzarova G.R. et al. Obezbolivanie vzroslykh i detei pri okazanii meditsinskoi pomoshchi. Metodicheskie rekomendatsii. FGBOU VO RNIMU im. N.I.Pirogova Minzdrava Rossii, 2016 (in Russian).]
36. Абузарова Г.Р. Лечение болевого синдрома у онкологических больных. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 278–88.
[Abuzarova G.R. Lechenie bolevogo sindroma u onkologicheskikh bol'nykh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 278–88 (in Russian).]
37. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5 Suppl. 1): S88–94.
38. Cheson BD et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification. J Clin Oncol 2014; 32 (27): 3059–67.
39. Solal-Céligny P et al. Follicular lymphoma international prognostic index. Blood 2004; 104 (5): 1258–65.
40. Buske C et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108 (5): 1504–8.
41. Federico M et al. Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27 (27): 4555–62.
42. Yelvington BJ. Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma. J Adv Pract Oncol 2018; 9 (5): 530–4.
43. Davies A et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Adv Ther 2017; 34 (10): 2210–31.
44. García‐Muñoz R et al. Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study. Br J Haematol 2020; 188 (5): 661–73.
45. Macdonald D et al. A canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma. Curr Oncol 2017; 24 (1): 33–9.
46. Huang YH et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31 (22): 2765–72.
47. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.
48. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on interim-PET scan in lymphoma. Leukemia Lymphoma 2009; 50 (8): 1257–60.
49. Khorana A et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10): 4902–7.
2. Armitage JO. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997; 89 (11): 3909–18.
3. Babicheva L.G., Tumian G.S., Kravchenko S.K. Follikuliarnaia limfoma. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 43–52 (in Russian).
4. Demina E.A. et al. Obshchie printsipy diagnostiki limfom. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 9–27 (in Russian).
5. Mukhortova O.V. Ispol'zovanie PET/KT pri limfoproliferativnykh zabolevaniiakh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 168–79 (in Russian).
6. Krivolapov Iu.A., Leenman E.E. Morfologicheskaia diagnostika limfom. Saint Petersburg: Kosta, 2006 (in Russian).
7. Bokeriia L.A., Zatevakhin I.I., Kirienko A.I. Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniiu i profilaktike venoznykh tromboembolicheskikh oslozhnenii (VTEO). Flebologiia. 2015; 4 (2): 3–52 (in Russian).
8. Kirienko A.I., Galstian G.M., Savchenko V.G. Profilaktika venoznykh tromboembolicheskikh oslozhnenii pri limfoproliferativnykh zabolevaniiakh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 268–78 (in Russian).
9. Shmakov R.G., Demina E.A. Limfomy i beremennost'. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 143–50 (in Russian).
10. Zelenetz AD et al. B-cell lymphomas. NCCN Clinical Practice Guidelines in Oncology. Version 5. 2019.
11. Dreyling M et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl. 5): v83–v90.
12. Campbell BA et al. Long-term outcomes for patients with limited stage follicular lymphoma involved regional radiotherapy versus involved node radiotherapy. Cancer 2010; 116 (16): 3797–806.
13. Wilder RB et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001; 51 (5) 1219–27.
14. Brady JL et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: A collaborative study by ILROG. Blood 2019; 133 (3): 237–45.
15. Ardeshna KM et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial. Lancet Oncol 2014; 15 (4): 424–35.
16. Hiddemann W et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol 2018; 36 (23): 2395–404.
17. Cheson BD et al. Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol 2018; 36 (22): 2259–66.
18. Flinn IW et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123 (19): 2944–52.
19. Dührsen U et al. Rituximab maintenance therapy of follicular lymphoma in clinical practice. Cancer Med 2018; 7 (7): 2903–12.
20. Poddubnaia I.V. Retsidivy follikuliarnoi limfomy: problemy i puti resheniia. Journal of Modern Oncology. 2011; 1: 10–5 (in Russian).
21. Leonard JP et al. AUGMENT: A Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019; 37 (14): 1188–99.
22. Sehn LH et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 2016; 17 (8): 1081–93.
23. Godfrey J, Leukam MJ, Smith SM. An update in treating transformed lymphoma. Best Pract Res Clin Haematol 2018; 31 (3): 251–61.
24. Grignano et al. Radiotherapy of relapse-refractory follicular lymphoma. Cancer Radiother 2018; 22 (2): 126–30.
25. Attarbaschi A et al. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a "watch and wait" strategy after complete resection. Ann Hematol 2013; 92 (11): 1537–41.
26. Liu Q et al. Follicular lymphomas in children and young adults: A comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol 2013; 37 (3): 333–43.
27. Kumar R et al. Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma. Pediatr. Blood Cancer 2011; 57 (2): 317–20.
28. Cheson BD et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25 (5): 579–86.
29. Bariakh E.A., Miakova N.V., Poddubnaia I.V. Profilaktika i lechenie sindroma lizisa opukholi. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 251–3 (in Russian).
30. Aapro M et al. Clinical recommendations for the treatment of anemia in patients with malignant neoplasms. Moscow: Association of Oncologists of Russia, 2014 (in Russian).
31. Orlova R.V. et al. Prakticheskie rekomendatsii po lecheniiu anemii pri zlokachestvennykh novoobrazovaniiakh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; p. 494–501 (in Russian).
32. Vladimirova L.Iu. et al. Prakticheskie rekomendatsii po profilaktike i lecheniiu toshnoty i rvoty u onkologicheskikh bol'nykh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; p. 502–11 (in Russian).
33. Konstantinova T.S., Kliasova G.A., Kaplanov K.D. Lechenie i profilaktika infektsionnykh oslozhnenii u patsientov s limfoproliferativnymi zabolevaniiami. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 289–311 (in Russian).
34. Srivastava S, Wood P. Secondary antibody deficiency-causes and approach to diagnosis. Clin Med 2016.
35. Abuzarova G.R. et al. Obezbolivanie vzroslykh i detei pri okazanii meditsinskoi pomoshchi. Metodicheskie rekomendatsii. FGBOU VO RNIMU im. N.I.Pirogova Minzdrava Rossii, 2016 (in Russian).
36. Abuzarova G.R. Lechenie bolevogo sindroma u onkologicheskikh bol'nykh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 278–88 (in Russian).
37. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5 Suppl. 1): S88–94.
38. Cheson BD et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification. J Clin Oncol 2014; 32 (27): 3059–67.
39. Solal-Céligny P et al. Follicular lymphoma international prognostic index. Blood 2004; 104 (5): 1258–65.
40. Buske C et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108 (5): 1504–8.
41. Federico M et al. Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27 (27): 4555–62.
42. Yelvington BJ. Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma. J Adv Pract Oncol 2018; 9 (5): 530–4.
43. Davies A et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Adv Ther 2017; 34 (10): 2210–31.
44. García‐Muñoz R et al. Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study. Br J Haematol 2020; 188 (5): 661–73.
45. Macdonald D et al. A canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma. Curr Oncol 2017; 24 (1): 33–9.
46. Huang YH et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31 (22): 2765–72.
47. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.
48. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on interim-PET scan in lymphoma. Leukemia Lymphoma 2009; 50 (8): 1257–60.
49. Khorana A et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10): 4902–7.
2. Armitage JO. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997; 89 (11): 3909–18.
3. Бабичева Л.Г., Тумян Г.С., Кравченко С.К. Фолликулярная лимфома. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 43–52.
[Babicheva L.G., Tumian G.S., Kravchenko S.K. Follikuliarnaia limfoma. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 43–52 (in Russian).]
4. Демина Е.А. и др. Общие принципы диагностики лимфом. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 9–27.
[Demina E.A. et al. Obshchie printsipy diagnostiki limfom. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 9–27 (in Russian).]
5. Мухортова О.В. Использование ПЭТ/КТ при лимфопролиферативных заболеваниях. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 168–79.
[Mukhortova O.V. Ispol'zovanie PET/KT pri limfoproliferativnykh zabolevaniiakh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 168–79 (in Russian).]
6. Криволапов Ю.А., Леенман Е.Е. Морфологическая диагностика лимфом. СПб.: Коста, 2006.
[Krivolapov Iu.A., Leenman E.E. Morfologicheskaia diagnostika limfom. Saint Petersburg: Kosta, 2006 (in Russian).]
7. Бокерия Л.А., Затевахин И.И., Кириенко А.И. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015; 4 (2): 3–52.
[Bokeriia L.A., Zatevakhin I.I., Kirienko A.I. Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniiu i profilaktike venoznykh tromboembolicheskikh oslozhnenii (VTEO). Flebologiia. 2015; 4 (2): 3–52 (in Russian).]
8. Кириенко А.И., Галстян Г.М., Савченко В.Г. Профилактика венозных тромбоэмболических осложнений при лимфопролиферативных заболеваниях. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 268–78.
[Kirienko A.I., Galstian G.M., Savchenko V.G. Profilaktika venoznykh tromboembolicheskikh oslozhnenii pri limfoproliferativnykh zabolevaniiakh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 268–78 (in Russian).]
9. Шмаков Р.Г., Демина Е.А. Лимфомы и беременность. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 143–50.
[Shmakov R.G., Demina E.A. Limfomy i beremennost'. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 143–50 (in Russian).]
10. Zelenetz AD et al. B-cell lymphomas. NCCN Clinical Practice Guidelines in Oncology. Version 5. 2019.
11. Dreyling M et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl. 5): v83–v90.
12. Campbell BA et al. Long-term outcomes for patients with limited stage follicular lymphoma involved regional radiotherapy versus involved node radiotherapy. Cancer 2010; 116 (16): 3797–806.
13. Wilder RB et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001; 51 (5) 1219–27.
14. Brady JL et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: A collaborative study by ILROG. Blood 2019; 133 (3): 237–45.
15. Ardeshna KM et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial. Lancet Oncol 2014; 15 (4): 424–35.
16. Hiddemann W et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol 2018; 36 (23): 2395–404.
17. Cheson BD et al. Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol 2018; 36 (22): 2259–66.
18. Flinn IW et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123 (19): 2944–52.
19. Dührsen U et al. Rituximab maintenance therapy of follicular lymphoma in clinical practice. Cancer Med 2018; 7 (7): 2903–12.
20. Поддубная И.В. Рецидивы фолликулярной лимфомы: проблемы и пути решения. Современная онкология. 2011; 1: 10–5.
[Poddubnaia I.V. Retsidivy follikuliarnoi limfomy: problemy i puti resheniia. Journal of Modern Oncology. 2011; 1: 10–5 (in Russian).]
21. Leonard JP et al. AUGMENT: A Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019; 37 (14): 1188–99.
22. Sehn LH et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 2016; 17 (8): 1081–93.
23. Godfrey J, Leukam MJ, Smith SM. An update in treating transformed lymphoma. Best Pract Res Clin Haematol 2018; 31 (3): 251–61.
24. Grignano et al. Radiotherapy of relapse-refractory follicular lymphoma. Cancer Radiother 2018; 22 (2): 126–30.
25. Attarbaschi A et al. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a "watch and wait" strategy after complete resection. Ann Hematol 2013; 92 (11): 1537–41.
26. Liu Q et al. Follicular lymphomas in children and young adults: A comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol 2013; 37 (3): 333–43.
27. Kumar R et al. Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma. Pediatr. Blood Cancer 2011; 57 (2): 317–20.
28. Cheson BD et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25 (5): 579–86.
29. Барях Е.А., Мякова Н.В., Поддубная И.В. Профилактика и лечение синдрома лизиса опухоли. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 251–3.
[Bariakh E.A., Miakova N.V., Poddubnaia I.V. Profilaktika i lechenie sindroma lizisa opukholi. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 251–3 (in Russian).]
30. Aapro M и др. Клинические рекомендации по лечению анемии у больных злокачественными новообразованиями. М.: Ассоциация онкологов России, 2014.
[Aapro M et al. Clinical recommendations for the treatment of anemia in patients with malignant neoplasms. Moscow: Association of Oncologists of Russia, 2014 (in Russian).]
31. Орлова Р.В. и др. Практические рекомендации по лечению анемии при злокачественных новообразованиях. Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018; с. 494–501.
[Orlova R.V. et al. Prakticheskie rekomendatsii po lecheniiu anemii pri zlokachestvennykh novoobrazovaniiakh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; p. 494–501 (in Russian).]
32. Владимирова Л.Ю. и др. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных. Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018; с. 502–11.
[Vladimirova L.Iu. et al. Prakticheskie rekomendatsii po profilaktike i lecheniiu toshnoty i rvoty u onkologicheskikh bol'nykh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; p. 502–11 (in Russian).]
33. Константинова Т.С., Клясова Г.А., Капланов К.Д. Лечение и профилактика инфекционных осложнений у пациентов с лимфопролиферативными заболеваниями. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 289–311.
[Konstantinova T.S., Kliasova G.A., Kaplanov K.D. Lechenie i profilaktika infektsionnykh oslozhnenii u patsientov s limfoproliferativnymi zabolevaniiami. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 289–311 (in Russian).]
34. Srivastava S, Wood P. Secondary antibody deficiency-causes and approach to diagnosis. Clin Med 2016.
35. Абузарова Г.Р. и др. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И.Пирогова Минздрава России, 2016.
[Abuzarova G.R. et al. Obezbolivanie vzroslykh i detei pri okazanii meditsinskoi pomoshchi. Metodicheskie rekomendatsii. FGBOU VO RNIMU im. N.I.Pirogova Minzdrava Rossii, 2016 (in Russian).]
36. Абузарова Г.Р. Лечение болевого синдрома у онкологических больных. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 278–88.
[Abuzarova G.R. Lechenie bolevogo sindroma u onkologicheskikh bol'nykh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 278–88 (in Russian).]
37. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5 Suppl. 1): S88–94.
38. Cheson BD et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification. J Clin Oncol 2014; 32 (27): 3059–67.
39. Solal-Céligny P et al. Follicular lymphoma international prognostic index. Blood 2004; 104 (5): 1258–65.
40. Buske C et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108 (5): 1504–8.
41. Federico M et al. Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27 (27): 4555–62.
42. Yelvington BJ. Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma. J Adv Pract Oncol 2018; 9 (5): 530–4.
43. Davies A et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Adv Ther 2017; 34 (10): 2210–31.
44. García‐Muñoz R et al. Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study. Br J Haematol 2020; 188 (5): 661–73.
45. Macdonald D et al. A canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma. Curr Oncol 2017; 24 (1): 33–9.
46. Huang YH et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31 (22): 2765–72.
47. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.
48. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on interim-PET scan in lymphoma. Leukemia Lymphoma 2009; 50 (8): 1257–60.
49. Khorana A et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10): 4902–7.
________________________________________________
2. Armitage JO. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997; 89 (11): 3909–18.
3. Babicheva L.G., Tumian G.S., Kravchenko S.K. Follikuliarnaia limfoma. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 43–52 (in Russian).
4. Demina E.A. et al. Obshchie printsipy diagnostiki limfom. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 9–27 (in Russian).
5. Mukhortova O.V. Ispol'zovanie PET/KT pri limfoproliferativnykh zabolevaniiakh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 168–79 (in Russian).
6. Krivolapov Iu.A., Leenman E.E. Morfologicheskaia diagnostika limfom. Saint Petersburg: Kosta, 2006 (in Russian).
7. Bokeriia L.A., Zatevakhin I.I., Kirienko A.I. Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniiu i profilaktike venoznykh tromboembolicheskikh oslozhnenii (VTEO). Flebologiia. 2015; 4 (2): 3–52 (in Russian).
8. Kirienko A.I., Galstian G.M., Savchenko V.G. Profilaktika venoznykh tromboembolicheskikh oslozhnenii pri limfoproliferativnykh zabolevaniiakh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 268–78 (in Russian).
9. Shmakov R.G., Demina E.A. Limfomy i beremennost'. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 143–50 (in Russian).
10. Zelenetz AD et al. B-cell lymphomas. NCCN Clinical Practice Guidelines in Oncology. Version 5. 2019.
11. Dreyling M et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl. 5): v83–v90.
12. Campbell BA et al. Long-term outcomes for patients with limited stage follicular lymphoma involved regional radiotherapy versus involved node radiotherapy. Cancer 2010; 116 (16): 3797–806.
13. Wilder RB et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001; 51 (5) 1219–27.
14. Brady JL et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: A collaborative study by ILROG. Blood 2019; 133 (3): 237–45.
15. Ardeshna KM et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial. Lancet Oncol 2014; 15 (4): 424–35.
16. Hiddemann W et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol 2018; 36 (23): 2395–404.
17. Cheson BD et al. Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol 2018; 36 (22): 2259–66.
18. Flinn IW et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123 (19): 2944–52.
19. Dührsen U et al. Rituximab maintenance therapy of follicular lymphoma in clinical practice. Cancer Med 2018; 7 (7): 2903–12.
20. Poddubnaia I.V. Retsidivy follikuliarnoi limfomy: problemy i puti resheniia. Journal of Modern Oncology. 2011; 1: 10–5 (in Russian).
21. Leonard JP et al. AUGMENT: A Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019; 37 (14): 1188–99.
22. Sehn LH et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 2016; 17 (8): 1081–93.
23. Godfrey J, Leukam MJ, Smith SM. An update in treating transformed lymphoma. Best Pract Res Clin Haematol 2018; 31 (3): 251–61.
24. Grignano et al. Radiotherapy of relapse-refractory follicular lymphoma. Cancer Radiother 2018; 22 (2): 126–30.
25. Attarbaschi A et al. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a "watch and wait" strategy after complete resection. Ann Hematol 2013; 92 (11): 1537–41.
26. Liu Q et al. Follicular lymphomas in children and young adults: A comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol 2013; 37 (3): 333–43.
27. Kumar R et al. Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma. Pediatr. Blood Cancer 2011; 57 (2): 317–20.
28. Cheson BD et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25 (5): 579–86.
29. Bariakh E.A., Miakova N.V., Poddubnaia I.V. Profilaktika i lechenie sindroma lizisa opukholi. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 251–3 (in Russian).
30. Aapro M et al. Clinical recommendations for the treatment of anemia in patients with malignant neoplasms. Moscow: Association of Oncologists of Russia, 2014 (in Russian).
31. Orlova R.V. et al. Prakticheskie rekomendatsii po lecheniiu anemii pri zlokachestvennykh novoobrazovaniiakh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; p. 494–501 (in Russian).
32. Vladimirova L.Iu. et al. Prakticheskie rekomendatsii po profilaktike i lecheniiu toshnoty i rvoty u onkologicheskikh bol'nykh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; p. 502–11 (in Russian).
33. Konstantinova T.S., Kliasova G.A., Kaplanov K.D. Lechenie i profilaktika infektsionnykh oslozhnenii u patsientov s limfoproliferativnymi zabolevaniiami. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 289–311 (in Russian).
34. Srivastava S, Wood P. Secondary antibody deficiency-causes and approach to diagnosis. Clin Med 2016.
35. Abuzarova G.R. et al. Obezbolivanie vzroslykh i detei pri okazanii meditsinskoi pomoshchi. Metodicheskie rekomendatsii. FGBOU VO RNIMU im. N.I.Pirogova Minzdrava Rossii, 2016 (in Russian).
36. Abuzarova G.R. Lechenie bolevogo sindroma u onkologicheskikh bol'nykh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 278–88 (in Russian).
37. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5 Suppl. 1): S88–94.
38. Cheson BD et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification. J Clin Oncol 2014; 32 (27): 3059–67.
39. Solal-Céligny P et al. Follicular lymphoma international prognostic index. Blood 2004; 104 (5): 1258–65.
40. Buske C et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108 (5): 1504–8.
41. Federico M et al. Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27 (27): 4555–62.
42. Yelvington BJ. Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma. J Adv Pract Oncol 2018; 9 (5): 530–4.
43. Davies A et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Adv Ther 2017; 34 (10): 2210–31.
44. García‐Muñoz R et al. Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study. Br J Haematol 2020; 188 (5): 661–73.
45. Macdonald D et al. A canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma. Curr Oncol 2017; 24 (1): 33–9.
46. Huang YH et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31 (22): 2765–72.
47. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.
48. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on interim-PET scan in lymphoma. Leukemia Lymphoma 2009; 50 (8): 1257–60.
49. Khorana A et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10): 4902–7.
Авторы
Л.Г. Бабичева1, Г.С. Тумян1,2, Е.А. Османов2,3, С.К. Кравченко4, Н.А. Фалалеева5, Д.Н. Стефанов6, И.В. Поддубная1, Н.В. Мякова6, А.Г. Румянцев6, А.А. Масчан6, В.В. Птушкин7, В.В. Байков8, А.М. Ковригина4,9, Ю.А. Криволапов10, Д.М. Коновалов6, А.А. Невольских5, С.А. Иванов5, Ж.В. Хайлова5, Т.Г. Геворкян2
1 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России, Москва, Россия;
3 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
4 ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия;
5 Медицинский радиологический научный центр им. А.Ф. Цыба – филиал ФГБУ «Научный медицинский исследовательский центр радиологии» Минздрава России, Обнинск, Россия;
6 ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии
им. Дмитрия Рогачева» Минздрава России, Москва, Россия;
7 ГБУЗ «Городская клиническая больница им. С.П. Боткина» Департамента здравоохранения г. Москвы, Москва, Россия;
8 ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, Санкт-Петербург, Россия;
9 ФГБОУ ДПО «Институт повышения квалификации» ФМБА России, Москва, Россия;
10 ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России, Санкт-Петербург, Россия
1 Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
2 Blokhin National Medical Research Center of Oncology, Moscow, Russia;
3 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
4 National Medical Research Center of Hematology, Ministry of Health of Russia, Moscow, Russia;
5 Tsyba Medical Radiological Scientific Center – branch of Scientific Medical Research Center of Radiology, Obninsk, Russia;
6 Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia;
7 Botkin City Clinical Hospital, Moscow, Russia;
8 Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia;
9 Institute of Advanced Studies, Moscow, Russia;
10 Mechnikov North-Western State Medical University, Saint Petersburg, Russia
1 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России, Москва, Россия;
3 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
4 ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия;
5 Медицинский радиологический научный центр им. А.Ф. Цыба – филиал ФГБУ «Научный медицинский исследовательский центр радиологии» Минздрава России, Обнинск, Россия;
6 ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии
им. Дмитрия Рогачева» Минздрава России, Москва, Россия;
7 ГБУЗ «Городская клиническая больница им. С.П. Боткина» Департамента здравоохранения г. Москвы, Москва, Россия;
8 ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, Санкт-Петербург, Россия;
9 ФГБОУ ДПО «Институт повышения квалификации» ФМБА России, Москва, Россия;
10 ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России, Санкт-Петербург, Россия
________________________________________________
1 Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
2 Blokhin National Medical Research Center of Oncology, Moscow, Russia;
3 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
4 National Medical Research Center of Hematology, Ministry of Health of Russia, Moscow, Russia;
5 Tsyba Medical Radiological Scientific Center – branch of Scientific Medical Research Center of Radiology, Obninsk, Russia;
6 Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia;
7 Botkin City Clinical Hospital, Moscow, Russia;
8 Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia;
9 Institute of Advanced Studies, Moscow, Russia;
10 Mechnikov North-Western State Medical University, Saint Petersburg, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.